Cargando…

Impact of Body Mass Index on Survival of Metastatic Renal Cancer

Obesity has been established as a risk factor for renal cell carcinoma (RCC). Recently, studies have described obesity as a probable protecting factor in the metastatic stage of RCC. In this study, we assessed the relationship between body mass index (BMI) and overall survival in patients under syst...

Descripción completa

Detalles Bibliográficos
Autores principales:	Plonski, Jose Javier Salgado, Fernández-Pello, Sergio, Jiménez, Laura Rúger, Rodríguez, Iván González, Calvar, Laura Alonso, Villamil, Luis Rodríguez
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Codon Publications 2021
Materias:	Kidney Cancer: Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8336599/ https://www.ncbi.nlm.nih.gov/pubmed/34414066 http://dx.doi.org/10.15586/jkcvhl.v8i2.169

Ejemplares similares

Impact of Body Mass Index on Survival Outcomes of Patients with Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: A Systematic Review and Meta-analysis
por: Takemura, Kosuke, et al.
Publicado: (2022)

Local Treatment of Recurrent Renal Cell Carcinoma May Have a Significant Survival Effect Across All Risk-of-recurrence Groups
por: Marconi, Lorenzo, et al.
Publicado: (2022)

The Metastatic Risk of Renal Cell Carcinoma by Primary Tumor Size and Subtype
por: Monda, Steven M., et al.
Publicado: (2023)

New-onset Chronic Kidney Disease After Surgery for Localised Renal Masses in Patients with Two Kidneys and Preserved Renal Function: A Contemporary Multicentre Study
por: Pecoraro, Alessio, et al.
Publicado: (2023)

Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era
por: Shah, Neil J., et al.
Publicado: (2023)

Utilization of Renal Mass Biopsy for T1 Renal Lesions across Michigan: Results from MUSIC-KIDNEY, A Statewide Quality Improvement Collaborative
por: Patel, Amit K., et al.
Publicado: (2021)

Effect of Inferior Vena Cava Tumor Thrombus on Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Cytoreductive Nephrectomy
por: Hoeh, Benedikt, et al.
Publicado: (2022)

Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study
por: Lindskog, Magnus, et al.
Publicado: (2022)

Selective Use of Neoadjuvant Targeted Therapy Is Associated with Greater Achievement of Partial Nephrectomy for High-complexity Renal Masses in a Solitary Kidney
por: Attawettayanon, Worapat, et al.
Publicado: (2023)

RPN (Radius, Position of tumour, iNvasion of renal sinus) Classification and Nephrometry Scoring System: An Internationally Developed Clinical Classification To Describe the Surgical Difficulty for Renal Masses for Which Robotic Partial Nephrectomy Is Planned
por: Agarwal, Dinesh K., et al.
Publicado: (2023)

Initial Observation of a Large Proportion of Patients Presenting with Clinical Stage T1 Renal Masses: Results from the MUSIC-KIDNEY Statewide Collaborative
por: Patel, Amit K., et al.
Publicado: (2020)

Effectiveness of Thermal Ablation for Renal Cell Carcinoma after Prior Partial Nephrectomy
por: Abdelsalam, Mohamed E., et al.
Publicado: (2023)

Randomized Clinical Trial Comparing On-clamp Versus Off-clamp Laparoscopic Partial Nephrectomy for Small Renal Masses (CLOCK II Laparoscopic Study): A Intention-to-treat Analysis of Perioperative Outcomes
por: Bertolo, Riccardo, et al.
Publicado: (2022)

Differentiating Oncocytic Renal Tumors from Chromophobe Renal Cell Carcinoma: Comparison of Peak Early-phase Enhancement Ratio to Clinical Risk Factors and Rater Predictions
por: Patel, Hiten D., et al.
Publicado: (2022)

Characterizing Tumor Thrombus Arising from Non–Clear Cell Renal Cell Carcinoma
por: Rabinowitz, Matthew J., et al.
Publicado: (2022)

Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers
por: Gulati, Sakshi, et al.
Publicado: (2014)

Counterbalancing COVID-19 with Cancer Surveillance and Therapy: A Survey of Patients with Renal Cell Carcinoma
por: Staehler, Michael, et al.
Publicado: (2021)

Defining Tumour Shape Irregularity for Preoperative Risk Stratification of Clinically Localised Renal Cell Carcinoma
por: Tanaka, Hajime, et al.
Publicado: (2022)

Infiltration of M2 Macrophages and Regulatory T Cells Plays a Role in Recurrence of Renal Cell Carcinoma
por: Davidsson, Sabina, et al.
Publicado: (2020)

Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease—A National Register Study
por: Almdalal, Tarik, et al.
Publicado: (2022)

Plasma and Urine Free Glycosaminoglycans as Monitoring Biomarkers in Nonmetastatic Renal Cell Carcinoma—A Prospective Cohort Study
por: Gatto, Francesco, et al.
Publicado: (2022)

Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma
por: Udovicich, Cristian, et al.
Publicado: (2022)

Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma
por: Piccinelli, Mattia L., et al.
Publicado: (2023)

In Situ Metabolomics Expands the Spectrum of Renal Tumours Positive on (99m)Tc-sestamibi Single Photon Emission Computed Tomography/Computed Tomography Examination
por: Papathomas, Thomas, et al.
Publicado: (2020)

Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma
por: Lee, Chung-Han, et al.
Publicado: (2021)

Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
por: Bosma, Nicholas A., et al.
Publicado: (2022)

Can Molecular Classifications Help Tailor First-line Treatment of Metastatic Renal Cell Carcinoma? A Systematic Review of Available Models
por: Ouzaid, Idir, et al.
Publicado: (2022)

Systemic Treatment for Advanced and Metastatic Non-Clear Cell Renal Cell Carcinoma: Examining Modern Therapeutic Strategies for a Notoriously Challenging Malignancy
por: Drobner, Jake, et al.
Publicado: (2023)

Effects of Social Deprivation on the Proportion of Preemptive Kidney Transplantation: A Mediation Analysis
por: Calvar, Eve, et al.
Publicado: (2021)

Estimated Glomerular Filtration Rate Decline at 1 Year After Minimally Invasive Partial Nephrectomy: A Multimodel Comparison of Predictors
por: Crocerossa, Fabio, et al.
Publicado: (2022)

Second Primary Cancers After Kidney Cancers, and Kidney Cancers as Second Primary Cancers
por: Zheng, Guoqiao, et al.
Publicado: (2021)

Impact of Positive Surgical Margins After Partial Nephrectomy
por: Carvalho, João André Mendes, et al.
Publicado: (2020)

Risk Prediction Models for Kidney Cancer: A Systematic Review
por: Harrison, Hannah, et al.
Publicado: (2021)

Outcomes for Atypical Tumor Recurrences Following Minimally Invasive Kidney Cancer Operations
por: Russo, Paul, et al.
Publicado: (2022)

Association of Artificially Sweetened Beverage Consumption and Urinary Tract Cancers in the Women’s Health Initiative Observational Study
por: Ringel, Nancy E., et al.
Publicado: (2022)

Impact of Surgical Experience Before Robot-assisted Partial Nephrectomy on Surgical Outcomes: A Multicenter Analysis of 2500 Patients
por: Harke, Nina N., et al.
Publicado: (2022)

Impact of Partial Nephrectomy and Percutaneous Cryoablation on Short-term Health-related Quality of Life—A Prospective Comparative Cohort Study
por: Junker, Theresa, et al.
Publicado: (2022)

Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?
por: Fransen van de Putte, Elisabeth E., et al.
Publicado: (2023)

Off-clamp Versus On-clamp Robot-assisted Partial Nephrectomy: A Systematic Review and Quantitative Synthesis by the European Association of Urology Young Academic Urologists Renal Cancer Study Group
por: Shrivastava, Nikita, et al.
Publicado: (2023)

Partial Nephrectomy for T1b/T2 Renal Mass: An Added Shift from Radical Nephrectomy
por: Sharafeldeen, Mohamed, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mbn9tv1q9tqebss58emjonis5c